DNA repair and lung cancer

New Research on DNA Repair

Volumn , Issue , 2007, Pages 39-84

  Kiyohara, Chikako ^a   Takayama, Koichi ^a   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Base excision repair; Double strand DNA break repair; Genetic polymorphism; Lung cancer; Metaanalysis; Mismatch repair; Molecular epidemiology; Nucleotide excision repair

Indexed keywords

EID: 38049170189     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (232)

1. Pharoah PD, Dunning A., Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4: 850-60.
2. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005; 577: 275-83.
3. Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968; 218: 652-6.
4. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000; 21: 453-60.
5. Miller MC 3rd, Mohrenweiser HW, Bell DA. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 2001; 120: 269-80.
6. Tomkinson AE. Mackey, ZB. Structure and function of mammalian DNA ligases. Mutat Res 1988; 407: 1-9.
7. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002; 21: 8949-56.
8. Bootsma D, Kraemer KH, Cleaver JE, Hoeijmakers JH. Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. In Vogelstein B, Kinzler KW. (eds) The Genetic Basis of Human Cancer. McGraw-Hill, New York, NY, 1998; 245-274.
9. Kraemer KH. Sunlight and skin cancer: another link revealed. Proc Natl Acad Sci (USA) 1997; 94: 11-4.
10. van Steeg H, Kraemer KH. Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Mol Med Today 1999; 5: 86-94.
11. Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003; 85: 1101-11.
12. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
13. Thompson LH, Schild D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat Res 2001; 477: 131-53.
14. Haber JE. Partners and pathwaysrepairing a double-strand break. Trends Genet 2000; 16: 259-64.
15. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 2000; 92: 795-802.
16. Boultwood J. Ataxia telangiectasia gene mutations in leukaemia and lymphoma. J Clin Pathol 2001; 54: 512-6.
17. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat Res 2002; 509: 49-78.
18. Bachrati CZ, Hickson ID. RecQ helicases: suppressors of tumorigenesis and premature aging. Biochem J 2003; 374: 577-606.
19. Mohaghegh P, Hickson ID. Premature aging in RecQ helicase-deficient human syndromes. Int J Biochem Cell Biol 2002; 34: 1496-501.
20. Cheok CF, Bachrati CZ, Chan KL, Ralf C, Wu L, Hickson ID. Roles of the Bloom's syndrome helicase in the maintenance of genome stability. Biochem Soc Trans 2005; 33: 1456-9.
21. Bassing CH, Swat W, Alt FW. The mechanism andregulation of chromosomal V(D)J recombination. Cell 2002; 109: S45-S55.
22. Lieber MR, Ma Y, Pannicke U, Schwarz K. Mechanism and regulation of human nonhomologous DNA end-joining. Nat Rev Mol Cell Biol 2003; 4: 712-20.
23. Lieber MR, Ma Y, Pannicke U, Schwarz K. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA repair 2004; 3: 817-826.
24. Burma S, Chen DJ. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA repair 2004; 3: 909-918.
25. Eisen JA. A phylogenomic study of the MutS family of proteins. Nucleic Acids Res 1998; 26: 4291-300.
26. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Cur Opin Genet Dev 1999; 9: 89-96.
27. Muller A, Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest 2002; 20: 102-9.
28. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027-38.
29. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, Guan XY, Zhang J, Meltzer PS, Yu JW, Kao FT, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin JP, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, Delachapelle A, Kinzler KW, Vogelstein B. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-25.
30. Bronner CE, Baker SM, Morrison PT, Warren G., Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-61.
31. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, HaseltineWA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomaki P, Mechlin JP, Delachapelle A, Komzler KW, Vpgelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science1994; 263: 1625-9.
32. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005; 74: 681-710.
33. Flores-Rozas H, Kolodner RD. The Saccharomyces cerevisiae MLH3 gene functions in MSH3-dependent suppression of frameshift mutations. Proc Natl Acad Sci (USA) 1998; 95: 12404-9.
34. Wang TF, Kleckner N, Hunter N. Functional specificity of MutL homologs in yeast: evidence for three Mlh1-based heterocomplexes with distinct roles during meiosis in recombination and mismatch correction. Proc Natl Acad Sci (USA) 1999; 96: 13914-9.
35. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
36. Bocker T, Ruschoff J, Fishel R. Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects. Biochim Biophys Acta 1999; 1423: O1-O10.
37. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-9.
38. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nature Genet 1994; 6: 2273-10.
39. Dietmaier W, Wallinger S, Bocker T, Kullmann F, Fishel R, Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997; 57: 4749-56.
40. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91: 1194-210.
41. Livneh Z. DNA damage control by novel DNA polymerases: translesion replication and mutagenesis. J Biol Chem 2001; 276: 25639-42.
42. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92: 874-97.
43. Lippman SM, Spitz MR. Lung cancer chemoprevention: an integrated approach. J Clin Oncol 2001; 19: S74-82.
44. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92: 1764-72.
45. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 56: 4103-7.
46. Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, et al. Altered DNA repair capacity and bleomycin sensitivity as risk markers for nonsmall cell lung cancer. Int J Cancer 2001; 95: 86-91.
47. Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129.
48. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
49. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
50. Rosenquist A, Zharkov DO, Grollman AP. Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. Proc Natl Acad Sci (USA) 1997; 94: 7429-34.
51. Nishioka K, Ohtsubo T, Oda H, Fujiwara T, Kang D, Sugimachi K, Nakabeppu Y. Expression and differential intracellular localization of two major forms of human 8-oxoguanine DNA glycosylase encoded by alternatively spliced OGG1 mRNAs. Mol Biol Cell 1999; 10: 1637-52.
52. Weiss JM, Goode EL, Ladiges WC, Ulrich CM. Polymorphic variation in OGG1 and risk of cancer: A review of the functional and epidemiologic literature. Mol Carcinog 2005; 42: 127-41.
53. Lee AJ, Hodges NJ, Chipman JK. Interindividual variability in response to sodium dichromate-induced oxidative DNA damage: role of the Ser326Cys polymorphism in the DNA-repair protein of 8-oxo-7,8-dihydro-2'-deoxyguanosine DNA glycosylase 1. Cancer Epidemiol Biomarkers Prev 2005; 14: 497-505.
54. Sugimura H, Kohno T, Wakai K, Nagura K, Genka K, Igarashi H, Morris BJ, Baba S, Ohno Y, Gao C, Li Z, Wang J, Takezaki T, Tajima K, Varga T, Sawaguchi T, Lum JK, Martinson JJ, Tsugane S, Iwamasa T, Shinmura K, Yokota J. R hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1999; 8: 669-74.
55. Ito H, Hamajima N, Takezaki T, Matsuo K, Tajima K, Hatooka S, Mitsudomi T, Suyama M, Sato S, Ueda R. A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol 2002; 12: 258-65.
56. Sunaga N, Kohno T, Yanagitani N, Sugimura H, Kunitoh H, Tamura T, Takei Y, Tsuchiya S, Saito R, Yokota J. Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 2002; 11: 730-8.
57. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N, Rothman N. Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004; 25: 2177-81.
58. Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H. hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a caucasian population. Int J Cancer 2000; 88: 932-7.
59. Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Borel S, Hall J, Boffetta P. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 2005; 97: 567-76.
60. Le Marchand L, Donlon T, Lum-Jones A, Seifried A, Wilkens LR. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 409-12.
61. Park J, Chen L, Tockman MS, Elahi A, Lazarus P. The human 8-oxoguanine DNA Nglycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 2004; 14: 103-9.
62. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 2005; 162: 925-42.
63. Kohno T, Shinmura K, Tosaka M, Tani M, Kim SR, Sugimura H, Nohmi T, Kasai H, Yokota J. Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 1998; 16: 3219-25.
64. Dhenaut A, Boiteux S, Radicella JP. Characterization of the hOGG1 promoter and its expression during the cell cycle. Mutat Res 2000; 461: 109-18.
65. Vogel U, Nexo BA, Wallin H, Overvad K, Tjonneland A, Raaschou-Nielsen O. No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem Genet 2004; 42: 453-60.
66. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, Phillips DH, Canzian F, Haugen A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006; 27: 560-7.
67. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, Autrup H, Malaveille C, Peluso M, Airoldi L, Veglia F, Gormally E, Hoek G, Krzyzanowski M, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Palli D, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Vineis P. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006; 27: 997-1007.
68. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with DNA polymerase ß and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 1996; 24: 4387-94.
69. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-De Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998; 18: 3563-71.
70. Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, Weinfeld M, Caldecott KW. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 2001; 104: 107-17.
71. Vidal AE, Boiteux S, Hickson ID, Radicella JP. XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions. EMBO J 2001; 20: 6530-9.
72. Thompson LH, Brookman KW. Jones J, Allen SA, Carrano AV. Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Mol Cell Biol 1990; 10: 6160-71.
73. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58: 604-8.
74. Lunn RM, Langlois G., Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 1999; 59: 2557-61.
75. Savas S, Kim DY, Ahmad MF, Shariff M, Ozcelik H. Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 2004; 13: 801-7.
76. Lamerdin JE, Montgomery MA, Stilwagen SA, Scheidecker LK, Tebbs RS, Brookman KW, Thompson LH, Carrano AV. Genomic sequence comparison of the human and mouse XRCC1 DNA repair gene regions. Genomics 1995; 25: 547-54.
77. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001; 22: 593-7.
78. Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, Giffen CA, Erozan Y, Tockman MS, Taylor PR. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 119-23.
79. David-Beabes GL, London SJ. Genetic polymorphism of XRCC1 and lung cancer risk among African-Americans and Caucasians. Lung Cancer 2001; 34: 333-9.
80. Divine KK, Gilliland FD, Crowell RE, Stidley CA, Bocklage TJ, Cook DL, Belinsky SA. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001; 461: 273-8.
81. Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, Cho SS. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 2002; 23: 1321-5.
82. Park JY, Lee SY, Jeon HS, Bae NC, Chae SC, Joo S, Kim CH, Park JH, Kam S, Kim IS, Jung TH. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 23-7.
83. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, Taylor PR, Albanes D. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003; 191: 171-8.
84. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, Yasue T, Lee KM, Kang D, Yoo KY, Sato S, Ueda R, Tajima K. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis 2004; 25: 1395-401.
85. Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L, Kayser K, Dienemann H, Schulz V, Drings P, Bartsch H, Schmezer P. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004; 25: 2433-41.
86. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen 2004; 44: 74-82.
87. Zhang X, Miao X, Liang G, Hao B, Wang Y, Tan W, Li Y, Guo Y, He F, Wei Q, Lin D. Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. Cancer Res 2005; 65: 722-6.
88. Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 359-65.
89. Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med 2005; 16: 709-16.
90. Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, Welch R, Chanock S, Keohavong P, Donahue M, Zheng T, Caporaso N, Lan Q. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res 2005; 25: 537-42.
91. Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman B, Bell DA. Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 217-22.
92. Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL, Wallin H, Overvad K, Tjonneland A. A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis 2003; 24: 899-904.
93. Lindahl T. Recognition and processing of damaged DNA. J Cell Sci 1995; 19: S73-7.
94. Bennett RA, Wilson DM 3rd, Wong D, Demple B. Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway. Proc Natl Acad Sci (USA) 1997; 94: 7166-9.
95. Mitra S, Hazra TK, Roy R, Ikeda S, Biswas T, Lock J, Boldogh I, Izumi T. Complexities of DNA base excision repair in mammalian cells. Mol Cells 1997; 7: 305-12.
96. Izumi T, Hazra TK, Boldogh I, Tomkinson AE, Park MS, Ikeda S, Mitra S. Requirement for human AP endonuclease 1 for repair of 3-blocking damage at DNA single-strand breaks induced by reactive oxygen species. Carcinogenesis 2000; 21: 1329-34.
97. Hadi MZ, Coleman MA, Fidelis K, Mohrenweiser HW, Wilson DM 3rd. Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 2000; 28: 3871-9.
98. Wilson DM 3rd, Sofinowski TM, McNeill DR. Repair mechanisms for oxidative DNA damage. Front Biosci 2003; 8: d963-81.
99. Suh D, Wilson DM 3rd, Povirk LF. 3-phosphodiesterase activity of human apurinic/apyrimidinic endonuclease at DNA double-strand break ends. Nucleic Acids Res 1997; 25: 2495-500.
100. Ramana CV, Boldogh I, Izumi T, Mitra S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc Natl Acad Sci (USA) 1998; 95: 5061-6.
101. Wilson DM 3rd, Takeshita M, Grollman AP, Demple B. Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA. J Biol Chem 1995; 270: 16002-7.
102. Breen AP, Murphy JA. Reactions of oxyl radicals with DNA. J Free Radic Biol Med 1995; 18: 1033-77.
103. Sancar A. DNA repair in humans. Annu Rev Genet 1995; 29: 69-105.
104. Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, Broshears J, Koch M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001; 7: 824-30.
105. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-50.
106. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 2001; 22: 917-22.
107. Vineis P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int J Cancer 1997; 71: 1-3.
108. Nakachi K, Imai K, Hayashi S, Watanabe J, Kawajiri K. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1991; 51: 5177-80.
109. Coverley D, Kenny MK, Lane DP, Wood RD. A role for the human single-stranded DNA binding protein HSSB/RPA in an early stage of nucleotide excision repair. Nucleic Acids Res 1992; 20: 3873-80.
110. Sancar A. Excision repair in mammalian cells. J Biol Chem 1995; 270: 15915-8.
111. He Z, Henricksen LA, Wold MS, Ingles CJ. RPA involvement in the damagerecognition and incision steps of nucleotide excision repair. Nature 1995; 374: 566-9.
112. Aboussekhra A, Biggerstaff M, Shivji MK, Vilpo JA, Moncollin V, Podust VN, Protic M, Hubscher U, Egly JM, Wood RD. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell 1995; 80: 859-68
113. Mu D, Park CH, Matsunaga T, Hsu DS, Reardon JT, Sancar A. Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 1995; 270: 2415-2418.
114. Jones CJ, Wood RD. Preferential binding of the xeroderma pigmentosum group A complementing protein to damaged DNA. Biochemistry 1993; 32: 12096-104.
115. Burns JL, Guzder SN, Sung P, Prakash S, Prakash L. An affinity of human replication protein A for ultraviolet-damaged DNA. J Biol Chem 1996; 271: 11607-10.
116. Patrick SM, Turchi JJ. Human replication protein A preferentially binds cisplatindamaged duplex DNA in vitro. Biochemistry 1998; 37: 8808-15.
117. Matsuda T, Saijo M, Kuraoka I, Kobayashi T, Nakatsu Y, Nagai A, Enjoji T, Masutani C, Sugasawa K, Hanaoka F, Yasui A, Tanaka K. DNA repair protein XPA binds replication protein A (RPA). J Biol Chem 1995; 270: 4152-7.
118. Li L, Lu X, Peterson CA, Legerski RJ. An interaction between the DNA repair factor XPA and replication protein A appears essential for nucleotide excision repair. Mol Cell Biol 1995; 15: 5396-402.
119. Wakasugi M, Sancar A. Order of assembly of human DNA repair excision nuclease. J Biol Chem 274; 1999: 18759-68.
120. Sugasawa K, Ng JM, Masutani C, Iwai S, van der Spek PJ, Eker AP, Hanaoka F, Bootsma D, Hoeijmakers JH. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 1998; 2: 223-32.
121. Reardon JT, Nichols AF, Keeney S, Smith CA, Taylor JS, Linn S, Sancar A. Comparative analysis of binding of human damaged DNA-binding protein (XPE) and Escherichia coli damage recognition protein (UvrA) to the major ultraviolet photoproducts: Tc,s]T, Tt,s]T, T6-4]T, and TDewar]T. J Biol Chem 1993; 268: 21301-8.
122. Wakasugi M, Shimizu M, Morioka H, Linn S, Nikaido O, Matsunaga T. Damaged DNA-binding protein DDB stimulates the excision of cyclobutane pyrimidine dimers in vitro in concert with XPA and replication protein A. J Biol Chem 2001; 276: 15434-40.
123. Butkiewicz D, Rusin M, Harris CC, Chorazy M. Identification of four single nucleotide polymorphisms in DNA repair genes: XPA and XPB (ERCC3) in Polish population. Hum Mutat 2000; 15: 577-8.
124. Kozak M. Interpreting cDNA sequences: some insights from studies on translation. Mamm Genome 1996; 7: 563-74.
125. Wu X, Zhao H, Wei Q, et al. XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 2003; 24: 505-9.
126. Park JY, Park SH, Choi JE, Lee SY, Jeon HS, Cha SI, Kim CH, Park JH, Kam S, Park RW, Kim IS, Jung TH. Polymorphisms of the DNA repair gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 993-7.
127. Vogel U, Overvad K, Wallin H, Tjonneland A, Nexo BA, Raaschou-Nielsen O. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005; 222: 67-74.
128. van Duin M, Koken MH, van den Tol J, ten Dijke P, Odijk H, Westerveld A, Bootsma D, Hoeijmakers JH. Genomic characterization of the human DNA excision repair gene ERCC-1. Nucleic Acids Res 1987; 15: 9195-213.
129. Hoeijmakers HJ. Characterization of genes and proteins involved in excision repair of human cells. J Cell Sci 1987; 6: S111-25.
130. Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL, Bostick-Bruton F, Mitchell KC, Reed E. A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat Res 1997; 382: 13-20.
131. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11: 1513-30.
132. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS. Association between polymorphisms of ERCC1 and XPD and survival in non-smallcell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44: 311-6.
133. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555-60.
134. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Gil J, Mallik N, Lenz H-J. ERCC1 polymorphism is associated with differential ERCC1 gene expression. Proc AACR 2002; 93: 1591.
135. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003; 1: 162-6.
136. Winsey SL, Haldar NA, Marsh HP, Bunce M, Marshall SE, Harris AL, Wojnarowska F, Welsh KI. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000; 60: 5612-6.
137. Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, Bukowy Z, Wallin H, Overvad K, Tjonneland A, Nexo BA, Raaschou-Nielsen O. Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer. Mutat Res 2004; 546: 65-74.
138. Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, Su L, Christiani DC. Genesmoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 491-6.
139. Yin J, Vogel U, Guo L, Ma Y, Wang H. Lack of association between DNA repair gene ERCC1 polymorphism and risk of lung cancer in a Chinese population. Cancer Genet Cytogenet 2006; 164: 66-70.
140. Egly JM. The 14th Datta Lecture. TFIIH: from transcription to clinic. FEBS Lett 2001; 498: 124-8.
141. Schaeffer L, Moncollin V, Roy R, Staub A, Mezzina M, Sarasin A, Weeda G, Hoeijmakers JH, Egly JM. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J 1994; 13: 2388-92.
142. Coin F, Bergmann E, Tremeau-Bravard A, Egly JM. Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. EMBO J 1999; 18: 1357-66.
143. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Guo Z, Lei L, Mohrenweiser H, Wei Q. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-7.
144. Hou SM, Falt S, Angelini S, Yang K, Nyberg F, Lambert B, Hemminki K. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23: 599-603.
145. Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, Lynch TJ, Su L, Christiani DC. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 2002; 62: 1377-81.
146. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, Lin D. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 2003; 105: 669-73.
147. Hu Z, Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 2004; 46: 1-10.
148. Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 2005; 161: 1-14.
149. Xing D, Tan W, Wei Q, Lin D. Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. Lung Cancer 2002; 38: 123-9.
150. Shen M, Berndt SI, Rothman N, Demarini DM, Mumford JL, He X, Bonner MR, Tian L, Yeager M, Welch R, Chanock S, Zheng T, Caporaso N, Lan Q. Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China. Int J Cancer 2005; 116: 768-73.
151. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 911-2.
152. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, Rademakers S, de Rooij J, Jaspers NG, Hoeijmakers JH, Wood RD. Xeroderma pigmentosum group F caused by a defect in a structurespecific DNA repair endonuclease. Cell 1996; 86: 811-22.
153. de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998; 273: 7835-42.
154. Matsunaga T, Park CH, Bessho T, Mu D, Sancar A. Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nuclease. J Biol Chem 1996; 271: 11047-50.
155. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem 1996; 65: 101-33.
156. Leeflang EP, Tavare S, Marjoram P, Neal CO, Srinidhi J, MacFarlane H, MacDonald ME, Gusella JF, de Young M, Wexler NS, Arnheim N. Analysis of germline mutation spectra at the Huntington's disease locus supports a mitotic mutation mechanism. Hum Mol Genet 1999; 8: 173-83.
157. Brookman KW, Lamerdin JE, Thelen MP, Hwang M, Reardon JT, Sancar A, Zhou ZQ, Walter CA, Parris CN, Thompson LH. ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. Mol Cell Biol 1996; 16: 6553-62.
158. Smith TR, Levine EA, Perrier ND, Miller MS, Freimanis RI, Lohman K, Case LD, Xu J, Mohrenweiser HW, Hu JJ. DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 1200-4.
159. Fan F, Liu C, Tavare S, Arnheim N. Polymorphisms in the human DNA repair gene XPF. Mutat Res 1999; 406: 115-20.
160. MacInnes MA, Dickson JA, Hernandez RR, Learmonth D, Lin GY, Mudgett JS, Park MS, Schauer S, Reynolds RJ, Strniste GF. Human ERCC5 cDNA-cosmid complementation for excision repair and bipartite amino acid domains conserved with RAD proteins of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Mol Cell Biol 1993; 13: 6393-402.
161. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 1997; 272: 16030-4.
162. Matsunaga T, Mu D, Park CH, Reardon JT, Sancar A. Human DNA repair excision nuclease: analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. J Biol Chem 1995; 270: 20862-9.
163. Constantinou A, Gunz D, Evans E, Lalle P, Bates PA, Wood RD, Clarkson SG. Conserved residues of human XPG protein important for nuclease activity and function in nucleotide excision repair. J Biol Chem 1999; 274: 5637-48.
164. Jeon HS, Kim KM, Park SH, Lee SY, Choi JE, Lee GY, Kam S, Park RW, Kim IS, Kim CH, Jung TH, Park JY. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer. Carcinogenesis 2003; 24: 1677-81.
165. Cui Y, Morgenstern H, Greenland S, Tashkin DP, Mao J, Cao W, Cozen W, Mack TM, Zhang ZF. Polymorphism of Xeroderma Pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx and esophagus. Int J Cancer 2006; 118: 714-20.
166. Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ. XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res 2000; 459: 89-97.
167. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999; 13: 2633-8.
168. Griffin CS. Aneuploidy, centrosome activity and chromosome instability in cells deficient in homologous recombination repair. Mutat Res 2002; 504: 149-55.
169. Matullo G, Palli D, Peluso M, Guarrera S, Carturan S, Celentano E, Krogh V, Munnia A, Tumino R, Polidoro S, Piazza A, Vineis P. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001; 22: 1437-45.
170. Araujo FD, Pierce AJ, Stark JM, Jasin M. Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 2002; 21: 4176-80.
171. Wang Y, Liang D, Spitz MR, Zhang K, Dong Q, Amos CI, Wu X. XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. Cancer 2003; 98: 1701-6.
172. Jacobsen NR, Raaschou-Nielsen O, Nexo B, Wallin H, Overvad K, Tjonneland A, Vogel U. XRCC3 polymorphisms and risk of lung cancer. Cancer Lett 2004; 213: 67-72.
173. Rafii S, O'Regan P, Xinarianos G, Azmy I, Stephenson T, Reed M, Meuth M, Thacker J, Cox A. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 2002; 11: 1 433-8.
174. Joenje H, Oostra AB, Wijker M, di Summa FM, van Berkel CG, Rooimans MA, Ebell W, van Weel M, Pronk JC, Buchwald M, Arwert F. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet 1997; 61: 940-4.
175. de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CG, Bosnoyan-Collins L, Alon N, Carreau M, Bender O, Demuth I, Schindler D, Pronk JC, Arwert F, Hoehn H, Digweed M, Buchwald M, Joenje H. The Fanconi anaemia group G gene is identical with human XRCC9. Nat Genet 1998; 20: 281-83.
176. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi anaemia by functional complementation. Nature 1992; 356: 763-7.
177. Consortium TFABC. Positional cloning of the Fanconi anaemia group A gene. Nat Genet 1996; 14: 324-8.
178. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen DF, Savoia A, Cheng NC, van Berkel CG, Strunk MH, Gille JJ, Pals G, Kruyt FA, Pronk JC, Arwert F, Buchwald M, Joenje H. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14: 320-3.
179. de Winter JP, Rooimans MA, van Der Weel L, van Berkel CG, Alon N, Bosnoyan-Collins L, de Groot J, Zhi Y, Waisfisz Q, Pronk JC, Arwert F, Mathew CG, Scheper RJ, Hoatlin ME, Buchwald M, Joenje H. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000; 24: 15-6.
180. Liu N, Lamerdin JE, Tucker JD, Zhou ZQ, Walter CA, Albala JS, Busch DB, Thompson LH. The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells. Proc Natl Acad Sci (USA) 1997; 94: 9232-7.
181. Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd, Hays L, Morgan WF, Petrini JH. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 1998; 93: 477-86.
182. Tauchi H, Matsuura S, Kobayashi J, Sakamoto S, Komatsu K. Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability. Oncogene 2002; 21: 8967-80.
183. Lan Q, Shen M, Berndt SI, Bonner MR, He X, Yeager M, Welch R, Keohavong P, Donahue M, Hainaut P, Chanock S. Smoky coal exposure, NBS1 polymorphisms, p53 protein accumulation, and lung cancer risk in Xuan Wei, China. Lung Cancer 2005; 49: 317-23.
184. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair deficient human cancers: toward a new concept of target genes for instability. Cancer Res 2002; 62: 2447-54.
185. Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic cancers. Hum Mutat Genet 1999; 8: 661-6.
186. Park JY, Jeon H-S, Park SH, et al. Microsatellite alteration in histologically normal lung tissue of patients with non-small cell lung cancer. Lung Cancer 2000; 30: 83-9.
187. Wu J, Gu L, Wang H, et al. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 1999; 19: 8292-301.
188. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci (USA) 1999; 96: 10764-9.
189. Mellon I, Rajpal DK, Koi M, Boland CR, Champe GN. Transcription-coupled repair deficiency and mutations in human mismatch repair genes. Science 1996; 272: 557-60.
190. Bertrand P, Tishkoff DX, Filosi N, Dasgupta R, Kolodner RD. Physical interaction between components of DNA mismatch repair and nucleotide excision repair. Proc Natl Acad Sci (USA) 1998; 95: 14278-83.
191. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, Shih CM, Chen CY. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 2003; 111: 887-95.
192. Kolodner RD. Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1995; 20: 397-401.
193. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat Res 2001; 486: 71-87.
194. Buersteddle JM, Alday P, Torhorst J, Weber W, Muller H, Scott R. Detection of new mutations in 6 out of Swiss HNPCC families by genomic sequencing of the MSH2 and MLH1 genes. J Med Genet 1995; 32: 909-12.
195. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parson RE, Jen J, Papadopoulos N, Peltromaki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995; 9: 48-55.
196. Wehner M, Buschhausen L, Lamberti C, Kruse R, Caspari R, Propping P, Friedl W. Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline mutations in hMSH2 or hMLH1 genes. Hum Mutat 1997; 10: 241-4.
197. Ito E, Yanagisawa Y, Iwahashi Y, Suzuki Y, Nagasaki H, Akiyama Y, Sugano S, Yuasa Y, Kazuo M. A core promoter and a frequent single-nucleotide polymorphism of the mismatch repair gene hMLH1. Biochem Biophys Res Commun 1999; 256: 488-94.
198. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57: 808-11.
199. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS. R Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer 2002; 86: 574-9.
200. Park SH, Lee GY, Jeon HS, Lee SJ, Kim KM, Jang SS, Kim CH, Lee WK, Kam S, Park RW, Kim IS, Jung TH, Park JY. 93G-->A polymorphism of hMLH1 and risk of primary lung cancer. Int J Cancer 2004; 112: 678-82.
201. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2004; 25: 1821-7.
202. Jung CY, Choi JE, Park JM, Chae MH, Kang HG, Kim KM, Lee SJ, Lee WK, Kam S, Cha SI, Kim CH, Han SB, Jung TH, Jeon SH, Park JY. Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 762-8.
203. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, Zuo ZF, Ashok TD, Mark EJ, Wain JC, Christiani DC, Kelsey KT. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21: 965-71.
204. Matullo G, Peluso M, Polidoro S, Guarrera S, Munnia A, Krogh V, Masala G, Berrino F, Panico S, Tumino R, Vineis P, Palli D. Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol Biomarkers Prev 2003; 12: 674-7.
205. Palli D, Russo A, Masala G, Saieva C, Guarrera S, Carturan S, Munnia A, Matullo G, Peluso M. DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample. Int J Cancer 2001; 94: 121-7.
206. Kozak M. Role of ATP in binding and migration of 40S ribosomal subunits. Cell 1990; 22: 459-67.
207. Kozak M. Initiation of translation in prokaryotes and eukaryotes. Gene 1999; 234: 187-208.
208. Kozak M. Adherence to the first-AUG rule when a second AUG codon follows closely upon the first. Proc Natl Acad Sci (USA) 1995; 92: 2662-6.
209. Kozak M. Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002; 299: 1-34.
210. Tanaka K, Miura N, Satokata I, Miyamoto I, Yoshida MC, Satoh Y, Kondo S, Yasui A, Okayama H, Okada Y. Analysis of a human DNA excision repair gene involved in group A xeroderma pigmentosum and containing a zinc-finger domain. Nature 1990; 348: 73-6.
211. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y. A common genetic polymorphism (46 C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
212. Kozak M. Primer extension analysis of eukaryotic ribosome-mRNA complexes. Nucleic Acids Res 1998; 26: 4853-9.
213. Sarasin A. An overview of the mechanisms of mutagenesis and carcinogenesis. Mutat Res 2003; 544: 99-106.
214. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X. From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Rep 2003; 2: 901-8.
215. Abdel-Rahman SZ, El-Zein RA. The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 2000; 159: 63-71.
216. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
217. Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000; 26: 362-4.
218. Spurdle AB, Hopper JL, Chen X, Dite GS, Cui J, McCredie MR, Giles GG, Ellis-Steinborner S, Venter DJ, Newman B, Southey MC, Chenevix-Trench G. The BRCA2 372 HH genotype is associated with risk of breast cancer in Australian women under age 60 years. Cancer Epidemiol Biomarkers Prev 2002; 11: 413-6.
219. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, Jiang R, Messer CJ, Chew A, Han JH, Duan J, Carr JL, Lee MS, Koshy B, Kumar AM, Zhang G, Newell WR, Windemuth A, Xu C, Kalbfleisch TS, Shaner SL, Arnold K, Schulz V, Drysdale CM, Nandabalan K, Judson RS, Ruano G, Vovis GF. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293: 489-93.
220. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000; 1: 15-26.
221. Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, Schork NJ. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease. Genome Res 2001; 11: 143-51.
222. Khoury M, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. Monographs in Epidemiology and Biostatistics, New York, NY Oxford University Press 1993; 144-145.
223. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 2001; 11: 2115-9.
224. Toniolo P, Boffetta P, Shuker D, Rothman N, Hulka B, Pearce N. Application of biomarkers in cancer epidemiology (IARC Scientific Publication no. 142), 1997.
225. Vineis P, Maltas M, Lang M, D'Errico A, Caporaso N, Cuzick J, Boffeta P. Metabolic polymorphisms and susceptibility to cancer (IARC Scientific Publication no. 148), 1999.
226. Todd JA. Interpretation of results from genetic studies of multifactorial diseases. Lancet 1999; 354: S115-6.
227. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. NQO1, MPO, and the risk of lung cancer: a HuGE review. Genet Med 2005; 7: 463-78.
228. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 2006; 17: 89-99.
229. Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 2002; 11: 1544-9.
230. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23: 381-7.
231. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin JM. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002; 37: 241-56.
232. Kiyohara C, Yoshimasu K, Shirakawa T, Hopkin JM. Genetic polymorphisms and environmental risk of lung cancer: a review. Rev Environ Health 2004; 19: 15-38.